SG3 Management’s Kyntra Bio KYNB Stock Holding History

SG3 Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-140	Closed	-$149K	–	1274
2020 Q4	$130K	Sell	140 -60	-30%	-$63.1K	﹤0.01%	906
2020 Q3	$206K	Buy	+200	New	+$215K	0.01%	723

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SG3 Management's KYNB Position: Q1 2021 in Review

SG3 Management sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 140 shares — an estimated $149K sold.

SG3 Management first reported a position in KYNB in Q3 2020 and held it in 2 quarters. The position peaked at $206K in Q3 2020. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

SG3 Management reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
SG3 Management sold 140 Kyntra Bio shares in Q1 2021, an estimated $149K.
SG3 Management first reported a position in Kyntra Bio in Q3 2020 and held it in 2 quarters.
SG3 Management's Kyntra Bio position peaked at $206K in Q3 2020.
198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on SG3 Management's 13F filing for Q1 2021, filed 17 May 2021.